Insulin degludec/insulin aspart versus biphasic insulin aspart 30 twice daily in insulin-experienced Japanese subjects with uncontrolled type 2 diabetes: Subgroup analysis of a Pan-Asian, treat-to-target Phase 3 Trial

What Was Tested

The paper reports a study of Insulin Aspart and NPH Insulin (isophane), published as a randomized controlled trial.

The present study was a subgroup analysis of a Pan-Asian Phase 3 open-label randomized treat-to-target trial evaluating insulin degludec/insulin aspart (IDegAsp) and biphasic insulin aspart 30 (BIAsp 30) in Japanese subjects with type 2 diabetes inadequately controlled on insulin.

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized and open-label.

Because people in this Insulin Aspart study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Nothing was hidden in this open-label Insulin Aspart study: the participants and staff both knew the treatment.

Changes in HbA1c , the proportion of responders reaching the HbA1c target, and changes in fasting plasma glucose, nine-point self-monitored plasma glucose profiles, and body weight were assessed.

What Was Measured

The present study was a subgroup analysis of a Pan-Asian Phase 3 open-label randomized treat-to-target trial evaluating insulin degludec/insulin aspart (IDegAsp) and biphasic insulin aspart 30 (BIAsp 30) in Japanese subjects with type 2 diabetes inadequately controlled on insulin.

PubMed files the paper under topics including Asian People, Biphasic Insulins, Blood Glucose, Diabetes Mellitus, Type 2, Diabetic Retinopathy, Glycated Hemoglobin and Hypertension.

The authors tagged it with the keywords glycemic control, insulin degludec/insulin aspart, nocturnal hypoglycemia and 血糖控制,德谷胰岛素/门冬胰岛素,夜间低血糖.

What This Means in Plain Language

The paper is a randomized and open-label study of Insulin Aspart and NPH Insulin (isophane).

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2017 (Journal of diabetes), a journal based in Australia.

More context: the Insulin Aspart compound page and the NPH Insulin (isophane) compound page.